• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Pixie Dust Technologies Inc.

    11/14/24 9:25:42 AM ET
    $PXDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $PXDT alert in real time by email
    SC 13D/A 1 ea022106104-13da1och_pixie.htm AMENDMENT NO. 1 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)* 

     

     

     

    Pixie Dust Technologies, Inc.

    (Name of Issuer)

     

    Common Shares, no par value

    (Title of Class of Securities)

     

    72582J103**

    (CUSIP Number)

     

    Yoichi Ochiai

    c/o Pixie Dust Technologies, Inc.

    2-2-1 Yaesu, Chuo-ku

    Tokyo, 104-0028, Japan

     

    Tel: +81(0)3-6910-3040

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    August 3, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

      

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d–1(e), 240.13d–1(f) or 240.13d–1(g), check the following box. ☐ 

     

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d–7 for other parties to whom copies are to be sent.

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    **There is no CUSIP number assigned to the common shares of the Issuer. CUSIP number 72582J103 has been assigned to the American Depositary Shares of the Issuer, which are listed on The NASDAQ Capital Market under the symbol “PXDT.” Each American Depositary Share represents one common share.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

     

     

    CUSIP No. 72582J103 SCHEDULE 13D

     

    1  

    NAME OF REPORTING PERSONS

     

    Yoichi Ochiai

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     

    (a) ☐ (b) ☐

    3  

    SEC USE ONLY

     

     

    4  

    SOURCE OF FUNDS (See Instructions)

     

    PF

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Japan

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

      7  

    SOLE VOTING POWER

     

    3,165,000(1)

      8  

    SHARED VOTING POWER

     

    0

      9  

    SOLE DISPOSITIVE POWER

     

    3,165,000(1)

      10  

    SHARED DISPOSITIVE POWER

     

    0

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,165,000(1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

    ☐

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    21.3%(2)

    14  

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

    (1)Represents (i) 3,162,600 common shares held directly by Mr. Ochiai, and (ii) an aggregate of 2,400 common shares that may be issued upon exercise of stock options previously issued to Mr. Ochiai, as determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

     

    (2)This percentage is based on 14,869,067 common shares outstanding as of April 30, 2024, as disclosed in the Issuer’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on August 22, 2024.

     

    2

     

     

    Item 1.Security and Issuer.

     

    This statement on Schedule 13D (this “Statement”) relates to the Common Shares, no par value (the “Common Shares”), of Pixie Dust Technologies, Inc., a joint stock corporation with limited liability organized under the laws of Japan (the “Issuer”), whose principal executive offices are located at 2-2-1 Yaesu, Chuo-ku, Tokyo, 104-0028, Japan.

     

    The Issuer’s American Depositary Shares (“ADSs”), each ADS representing one Common Share, are listed on The NASDAQ Capital Market under the symbol “PXDT.”

     

    Item 2.Identity and Background.

     

    (a)This Statement is being filed by Mr. Yoichi Ochiai (the “Reporting Person”).

     

    (b)The principal business address of the Reporting Person is c/o Pixie Dust Technologies, Inc., 2-2-1 Yaesu, Chuo-ku, Tokyo, 104-0028, Japan.

     

    (c)The Reporting Person is the Chief Executive Officer, a Director and the co-founder of the Issuer.

     

    (d)During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)During the last five years, the Reporting Person was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

     

    (f)The Reporting Person is a citizen of Japan.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    The Reporting Person is currently deemed to beneficially own an aggregate of 3,165,000 Common Shares, consisting of (i) 3,162,600 Common Shares held directly by the Reporting Person, and (ii) an aggregate of 2,400 Common Shares that may be issued upon exercise of certain stock options held by the Reporting Person which are exercisable within 60 days from the date hereof.

     

    The outstanding Common Shares currently beneficially owned by the Reporting Person were acquired by the Reporting Person over several years through various means, including (i) 3,066,000 Common Shares issued to the Reporting Person in exchange for his contribution of capital and expertise to the Issuer in connection with the formation of the Issuer entity in Japan, (ii) 96,600 Common Shares previously purchased by the Reporting Person from another existing shareholder of the Issuer, and (iii) an aggregate of 2,400 Common Shares that may be issued upon exercise of stock options granted to the Reporting Person pursuant to the Issuer’s Seventh Series of Stock Acquisition Rights for Common Shares in 2020 in connection with his service as the Issuer’s Chief Executive Officer, which are exercisable within 60 days from the date hereof.

     

    The sources of funding for the acquisitions of the Reporting Person’s Common Shares were the Reporting Person’s personal funds.

     

    IPO

     

    On August 3, 2023, the Issuer closed its initial public offering (the “IPO”) of 1,666,667 ADSs, each ADS representing one Common Share, at a price to the public of $9.00 per ADS, before underwriting discounts and commissions. The Reporting Person did not sell or offer to sell any of his Common Shares in the IPO.

     

    3

     

     

    Item 4.Purpose of Transaction.

     

    The information set forth in Item 3 above is hereby incorporated by reference in this Item 4.

     

    The Reporting Person is the co-founder of the Issuer and has served as its Chief Executive Officer and a representative director since the Issuer’s inception. Therefore, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to the transactions described in subparagraphs (a) through (j) of this Item 4 of Schedule 13D. The Reporting Person also reserves the right to formulate in the future plans or proposals which may relate to or result in the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

     

    Depending on the factors discussed herein, the Reporting Person may, from time to time, acquire additional Common Shares and/or retain and/or sell all or a portion of the Common Shares held by the Reporting Person in the open market or in privately negotiated transactions, and/or may distribute the Common Shares held by the Reporting Person to other entities. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person’s review of numerous factors, including, among other things, the price levels of the ADSs representing the Common Shares, general market and economic conditions, ongoing evaluation of the Issuer’s business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, investor’s need for liquidity, and other future developments. Any future acquisitions of the Common Shares by the Reporting Person will be subject to the Issuer’s policies, including its insider trading policy, as applicable.

     

    Item 5.Interest in Securities of the Issuer.

     

    (a)The responses of the Reporting Person to Rows (7) through (13) of the cover pages of this Statement are hereby

     

    (b)incorporated by reference in this Item 5. As of the date hereof, the Reporting Person may be deemed the beneficial owners of an aggregate of 3,165,000 Common Shares, representing approximately 21.3% of the issued and outstanding Common Shares of the Issuer.

     

    For purposes of this Statement, the Reporting Person has assumed that the total number of the Issuer’s issued and outstanding Common Shares is 14,869,067, as disclosed in the Issuer’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on August 22, 2024.

     

    (c)Except as described above, the Reporting Person has not effected any transactions in the Issuer’s securities within the past 60 days.

     

    (d)None.

     

    (e)Not applicable.

     

    Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    NA

     

    Item 7.Material to be Filed as Exhibits.

     

    None

     

    4

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    Date: November 14, 2024 By: /s/ Yoichi Ochiai
        Yoichi Ochiai

     

    5

     

    Get the next $PXDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PXDT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PXDT
    SEC Filings

    See more
    • SEC Form 6-K filed by Pixie Dust Technologies Inc.

      6-K - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/25/24 8:00:20 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Pixie Dust Technologies Inc.

      25 - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      11/4/24 4:30:02 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 6-K/A filed by Pixie Dust Technologies Inc.

      6-K/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Filer)

      10/24/24 1:55:49 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • /C O R R E C T I O N -- Pixie Dust Technologies/

      This release is announcing the amendment of the press release originally issued on October 23, 2024 to disclose the effective date of the delisting from NASDAQ and the Form 15-F filing from November 15, 2024, to November 14, 2024, wherever the date appears. Additionally, trading of the Company's American Depositary Receipts ("ADRs") on NASDAQ will be suspended effective prior to trading on November 14, 2024. No other changes have been made to the original press release. (Amendment)Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission. NEW YORK and TOKYO, Oct. 24, 2024 /PRNewswire/ - Pixie Dust Te

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Notice regarding Plan to Delist American Depositary Receipts from NASDAQ Capital Market and Deregister with U.S. Securities and Exchange Commission.

      NEW YORK and TOKYO, Oct. 23, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (the "Company") announced that its board of directors resolved, at its meeting held on October 23, 2024, to delist its American Depositary Receipts ("ADRs") from the NASDAQ Capital Market ("NASDAQ") and submit an application for deregistration with the U.S. Securities and Exchange Commission ("SEC"). The Company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. Plans regarding the delisting and deregistration are as follows: 1.                  Reasons for Applying for Delisting The Company listed its ADRs on NASDAQ in August 2023 to access the U.S. capital markets an

      10/23/24 4:30:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Financials

    Live finance-specific insights

    See more
    • Pixie Dust Technologies, Inc. Holds Fiscal Year 2024 Financial Results Briefing

      NEW YORK and TOKYO, Aug. 26, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Thursday, September 5, 2024 at 8:30 p.m. Eastern time (5:30 p.m. Pacific Time) to discuss its financial results for the fiscal year ended April 30, 2024. Date: 8:30 PM – 9:30 PM EST on September 5, 2024Location: Conference room A, Yaesu Central Tower, 2-2-1 Yaesu, Chuo-ku, Tokyo, JapanMethod: Off-line / On-line (real time)Topic: Fiscal Year 2024 Financial Results Briefing and Q&APresentation b

      8/26/24 4:15:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CORRECTION: Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 12, 2024

      NEW YORK and TOKYO, Feb. 11, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Monday, February 12, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/11/24 12:48:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Pixie Dust Technologies to Announce First-Half Fiscal Year 2024 Financial Results on February 13, 2024

      NEW YORK and TOKYO, Feb. 6, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, today announced that it will hold a conference call on Tuesday, February 13, 2024 at 8:00 p.m. Eastern time (5:00 p.m. Pacific Time) to discuss its financial results for the six months ended October 31, 2023. Pixie Dust Technologies CEO Yoichi Ochiai and COO Taiichiro Murakami will host the conference call, followed by a question-and-

      2/6/24 9:00:00 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:11:11 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:08:59 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pixie Dust Technologies Inc.

      SC 13G/A - PIXIE DUST TECHNOLOGIES, INC. (0001962845) (Subject)

      11/14/24 10:06:35 AM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $PXDT
    Leadership Updates

    Live Leadership Updates

    See more
    • Pixie Dust Technologies Announces CFO Transition

      NEW YORK and TOKYO, March 13, 2024 /PRNewswire/ - Pixie Dust Technologies, Inc. (NASDAQ:PXDT) (the "Company"), a Japanese technology company focused on commercializing innovative products and materials utilizing proprietary wave control technology, announced the appointment of Nobuhiro Takagi and Nobufusa Tarumi as co-Chief Financial Officer ("co-CFO"), effective March 13, 2024. Messrs. Takagi and Tarumi succeed Mr. Mamoru Miwa, whose resignation was not the result of any disagreement or conflict with the Company, its operations, policies, or practices. The role of the Company's Chief Accounting Officer ("CAO"), previously held by Nobuhiro Takagi, will be assumed by the co-CFOs.

      3/13/24 4:05:00 PM ET
      $PXDT
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care